# Lykos Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lykos-therapeutics

- Industry: Biotechnology
- Headquarters: San Jose, US
- Website: www.lykospbc.com/
- Latest round: Series A (Jan 5, 2024)
- Investors on record: 9

## About

Based in California, US, and founded in 2014, Lykos Therapeutics, formerly known as MAPS PBC, operates as a biopharmaceutical-based company providing research and development solutions for therapy to treat mental health and PTSD. In January 2024, Lykos Therapeutics raised an undisclosed amount of Series A funding led by Helena Capital, with participation from Vine Ventures, True Ventures, Bail Capital, KittyHawk Ventures, Satori Capital, Joe & Sandy Samberg Foundation, The Steven & Alexandra Cohen Foundation, Inc., Eir Pharmaceuticals, LLC, and Unlikely Collaborators Foundation.

Lykos Therapeutics provides research support for healthcare providers and develops therapies for post-traumatic stress disorder (PTSD) and other mental health conditions. The company offers a therapy training program to train therapists to provide clients with MDMA-assisted therapy. In addition, the company provides research on a variety of mental health topics, including anxiety research, social anxiety research, and psychedelic research.

## Funding rounds

- Series A, Jan 5, 2024 — True Ventures, Satori Capital, Helena Capital, Bail Capital, KittyHawk Ventures, Vine Ventures, Joe & Sandy Samberg Foundation, The Steven & Alexandra Cohen Foundation, Inc., Eir Pharmaceuticals, LLC

## Investors

- True Ventures (https://capitalatlas.ai/funds/true-ventures) — Series A
- Satori Capital (https://capitalatlas.ai/funds/satori-capital) — Series A
- Helena Capital (https://capitalatlas.ai/funds/helena-capital) — Series A
- Bail Capital (https://capitalatlas.ai/funds/bail-capital) — Series A
- KittyHawk Ventures (https://capitalatlas.ai/funds/kittyhawk-ventures) — Series A
- Vine Ventures — Series A
- Joe & Sandy Samberg Foundation — Series A
- The Steven & Alexandra Cohen Foundation, Inc. — Series A
- Eir Pharmaceuticals, LLC — Series A